Antengene Corp., of Shanghai, appointed John Chin chief business officer.
Arrowhead Pharmaceuticals Inc., of Pasadena, Calif., appointed James Hassard chief commercial officer.
Asclepix Therapeutics Inc., of Baltimore, appointed Theresa G. H. Heah chief medical officer.
Aveo Oncology Inc., of Cambridge, Mass., appointed Erick Lucera chief financial officer.
Azurrx Biopharma Inc., of Brooklyn, N.Y., appointed Daniel Schneiderman chief financial officer.
Beyondspring Inc., of New York, appointed James Tonra chief science officer. Its China subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd. appointed Roland Liu chief commercial officer.
Biodelivery Sciences International Inc., of Raleigh, N.C., appointed Kevin Ostrander senior vice president of business development.
Carisma Therapeutics Inc., of Philadelphia, appointed Debora Barton chief medical officer and Tom Wilton chief business officer.
Enochian Biosciences Inc., of Los Angeles, appointed Gregg Alton and Carol Brosgart to its board.
Fibrogen Inc., of San Francisco, appointed Enrique Conterno CEO and to its board.
Fulcrum Therapeutics Inc., of Cambridge, Mass., appointed Katina Dorton to its board and chair of its audit committee.
Kura Oncology Inc., of San Diego, appointed Kirsten Flowers chief commercial officer.
Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed Young Kwon chief financial and business officer, effective Jan. 8.
Phathom Pharmaceuticals Inc., of Buffalo Grove, Ill., appointed Martin J. Gilligan chief commercial officer.
Turning Point Therapeutics Inc., of San Diego, appointed Homa Yeganegi senior vice president, project team leader and head of medical affairs.